PIK3CA and neoplasm: Like mTOR inhibitors, the dual PI3K-mTOR inhibitors have shown promising anti-tumour activity in various preclinical models and tested in clinical trials of advanced solid tumours and non-Hodgkin lymphoma [269,270,271].